Journal article icon

Journal article

A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes

Abstract:

This phase 1b study evaluated glasdegib (100 mg once daily) + azacitidine in adults with newly diagnosed acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who were ineligible for intensive chemotherapy. Of 72 patients enrolled, 12 were in a lead-in safety cohort (LIC) and 60 were in the AML and MDS (including CMML) expansion cohorts. In the LIC, the safety profile of glasdegib + azacitidine ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1007/s00277-022-04853-4

Authors


More by this author
Role:
Author
ORCID:
0000-0003-2009-6524
Publisher:
Springer
Journal:
Annals of Hematology More from this journal
Volume:
101
Issue:
8
Pages:
1689-1701
Publication date:
2022-04-30
Acceptance date:
2022-04-20
DOI:
EISSN:
1432-0584
ISSN:
0939-5555
Pmid:
35488900
Language:
English
Keywords:
Pubs id:
1255373
Local pid:
pubs:1255373
Deposit date:
2022-09-26

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP